Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MGAM | O43451 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SI | P14410 | 1/20 | 0.32 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | ENPP2 | Q13822 | 4/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6276297 | 0.81 | MGAM (0.46) | MGAMGAASIMGAM2ENPP2 | |
| SCHEMBL11720069 | 0.81 | TSHR (0.43) | KDM4ELMNAENPP2 | |
| SCHEMBL23049686 | 0.80 | TSHR (0.33) | KDM4ELMNAMGAMGAASI | |
| SCHEMBL783557 | 0.79 | NAAA (0.40) | LMNAMGAMGAASIMGAM2 | |
| SCHEMBL3164875 | 0.79 | MAPT (0.34) | KDM4ELMNAENPP2 | |
| SCHEMBL610470 | 0.77 | MAPT (0.50) | KDM4ELMNAENPP2 | |
| SCHEMBL10918523 | 0.77 | TSHR (0.48) | KDM4ELMNAENPP2 | |
| SCHEMBL7603527 | 0.76 | ALOX15 (0.46) | KDM4ELMNACYP1A2 | |
| SCHEMBL2585074 | 0.76 | — | — | |
| SCHEMBL10922401 | 0.76 | MAPT (0.53) | KDM4ELMNAENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113336768-B | Multi-target tyrosine kinase inhibitor | 深圳海王医药科技研究院有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-113336768-A | Multi-target tyrosine kinase inhibitor | 深圳海王医药科技研究院有限公司 | 2021-09-03 | — | — | CN | disclosed |
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
| EP-2324041-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | Targanta Therapeutics Corp. (US) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010019511-A2 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | KDM4E 4561/4885LMNA 3377/4885MGAM 266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.